[Federal Register Volume 80, Number 233 (Friday, December 4, 2015)]
[Notices]
[Pages 75867-75868]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-30628]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-4399]
Determination That OPHTHAINE (proparacaine hydrochloride)
Solution and Other Drug Products Were Not Withdrawn From Sale for
Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) has
determined that the drug products listed in this document were not
withdrawn from sale for reasons of safety or effectiveness. This
determination means
[[Page 75868]]
that FDA will not begin procedures to withdraw approval of abbreviated
new drug applications (ANDAs) that refer to these drug products, and it
will allow FDA to continue to approve ANDAs that refer to the products
as long as they meet relevant legal and regulatory requirements.
FOR FURTHER INFORMATION CONTACT: Stacy Kane, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 51, Rm. 6236, Silver Spring, MD 20993-0002, 301-796-8363,
[email protected].
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products approved under an ANDA procedure. ANDA
applicants must, with certain exceptions, show that the drug for which
they are seeking approval contains the same active ingredient in the
same strength and dosage form as the ``listed drug,'' which is a
version of the drug that was previously approved. ANDA applicants do
not have to repeat the extensive clinical testing otherwise necessary
to gain approval of a new drug application (NDA).
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is generally known as the ``Orange
Book.'' Under FDA regulations, a drug is removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness, or if FDA determines that the
listed drug was withdrawn from sale for reasons of safety or
effectiveness (21 CFR 314.162).
Under Sec. 314.161(a) (21 CFR 314.161(a)), the Agency must
determine whether a listed drug was withdrawn from sale for reasons of
safety or effectiveness: (1) Before an ANDA that refers to that listed
drug may be approved, (2) whenever a listed drug is voluntarily
withdrawn from sale and ANDAs that refer to the listed drug have been
approved, and (3) when a person petitions for such a determination
under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if
FDA determines that a listed drug was withdrawn from sale for safety or
effectiveness reasons, the Agency will initiate proceedings that could
result in the withdrawal of approval of the ANDAs that refer to the
listed drug.
FDA has become aware that the drug products listed in the table in
this document are no longer being marketed.
------------------------------------------------------------------------
Application No. Drug Applicant
------------------------------------------------------------------------
NDA 008883............. OPHTHAINE (proparacaine Apothecon, Inc.
hydrochloride)
Solution/Drops;
Ophthalmic, 0.5%.
NDA 009053............. PURINETHOL Teva Pharmaceuticals
(mercaptopurine) USA.
Tablet; Oral, 50
milligrams (mg).
NDA 012427............. DIDREX (benzphetamine Pharmacia & Upjohn Co.
hydrochloride) Tablet;
Oral, 50 mg.
NDA 012583............. OPHTHETIC (proparacaine Allergan
hydrochloride) Pharmaceutical.
Solution/Drops;
Ophthalmic, 0.5%.
NDA 017716............. OVCON-35 (ethinyl Warner Chilcott LLC.
estradiol;
norethindrone) Tablet;
Oral-28, 0.035 mg; 0.4
mg.
NDA 018782............. NORDETTE-28 (ethinyl Teva Branded
estradiol; Pharmaceutical
levonorgestrel) Products R and D,
Tablet; Oral-28, 0.03 Inc.
mg; 0.15 mg.
NDA 021199............. QUIXIN (levofloxacin) Santen, Inc.
Solution/Drops;
Ophthalmic, 0.5%.
NDA 021595............. SANCTURA (trospium Allergan, Inc.
chloride) Tablet;
Oral, 20 mg.
NDA 021664............. BROMDAY (bromfenac Bausch & Lomb, Inc.
sodium) Solution/
Drops; Ophthalmic, EQ
0.09% acid.
NDA 022103............. SANCTURA XR (trospium Allergan, Inc.
chloride) Extended-
Release Capsule; Oral,
60 mg.
ANDA 060571............ MYCOSTATIN (nystatin) Delcor Asset Corp.
Ointment; Topical,
100,000 units/gram (g).
ANDA 060575............ MYCOSTATIN (nystatin) Do.
Cream; Topical,
100,000 units/g.
ANDA 060578............ MYCOSTATIN (nystatin) Do.
Powder; Topical
100,000 units/g.
ANDA 063116............ TOBRAMYCIN SULFATE Hospira, Inc.
(PHARMACY BULK)
(tobramycin sulfate)
Injectable; Injection,
EQ 40 mg base/
milliliter.
------------------------------------------------------------------------
FDA has reviewed its records and, under Sec. 314.161, has
determined that the drug products listed in this document were not
withdrawn from sale for reasons of safety or effectiveness.
Accordingly, the Agency will continue to list the drug products listed
in this document in the ``Discontinued Drug Product List'' section of
the Orange Book. The ``Discontinued Drug Product List'' identifies,
among other items, drug products that have been discontinued from
marketing for reasons other than safety or effectiveness.
Approved ANDAs that refer to the NDAs and ANDAs listed in this
document are unaffected by the discontinued marketing of the products
subject to those NDAs and ANDAs. Additional ANDAs that refer to these
products may also be approved by the Agency if they comply with
relevant legal and regulatory requirements. If FDA determines that
labeling for these drug products should be revised to meet current
standards, the Agency will advise ANDA applicants to submit such
labeling.
Dated: November 30, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-30628 Filed 12-3-15; 8:45 am]
BILLING CODE 4164-01-P